RESULTS We reviewed other CXCR4-targeting inhibitors to inform potential modifications of LY2510924 (1) that may enhance binding affinity (Supplemental Fig. 1). We considered the cyclic peptide 3 (FC131), which serves as the targeting pharmacophore for pentixafor/pentixather (Fig. 1). However, 3 possesses similar amino acids in its sequence that are essential for binding (D-Tyr, Arg, and Nal) and nonessential Arg and Gly, all of which are present on LY2510924 (26).
